Gal-3-silencing in prostate tumor cells by RNA interference or low/non-toxic doses of-docetaxel promotes vaccines' effectiveness
| Lysate used in vaccine | Tumor | N | Tumor incidence (%) | Tumor free-survival (days) | |
| No V1 | – | TC1-shGal-3 | 14 | 65* | 81±43* |
| No V2 | – | TC1-shCtrl | 23 | 92 | 39±11 |
| No V3 | – | TC1-shCtrl/DTX | 10 | 80 | 49±7 |
| VP1 | TC1-shCtrl | TC1-shGal-3 | 10 | 70 | 116±29 |
| VP2 | TC1-shGal-3 | TC1-shGal-3 | 10 | 0 | >275 |
| VP3 | TC1-shCtrl /DTX | TC1-shGal-3 | 10 | 0 | >275 |
| VP4 | TC1-shCtrl /DTX | TC1-shCtrl | 10 | 90 | 73±35 |
| VP5 | TC1-shGal-3 | TC1-shCtrl/DTX | 10 | 0 | >275 |
| VP5.2 | TC1-shGal-3 | TC1-shCtrl /DTX +challenge | 5 | 0 | >500 |
Tumor-bearing mice were vaccinated with BM-DC based vaccine loaded with tumor cells lysate expressing different levels of Gal-3 (Gal-3HIGH-vaccine for TC1-shCtrl; or Gal-3LOW-vaccine for TC1-shGal-3 and TC1-shCtrl/DTX) as indicated. The treatments with low and non-toxic doses of docetaxel (DTX) correspond to a 1 nM dose in cultured cells during 2 weeks before processing into lysates or 0.83 mg/kg (intraperitoneal injection) during 2 weeks, once a week for treated mice.
*p<0.05.
BM, bone marrow; DC, dendritic cells; Gal-3, galectin-3; TC1, TRAMP-C1.